INVESTIGATION OF PERIPHERAL ANALGESIC ACTIVITY OF OXICAMS AND ITS COMPOSITION WITH CAFFEINE

Anna Syrova¹, Larisa Lukyanova², Svetlana Kozub⁴, Oksana Zavada¹, Olga Levashova¹, Viktor Shaposhnik²
¹Kharkiv National Medical University, Medical and Bioorganic Chemistry Department, Kharkiv, Ukraine
²Kharkiv National Medical University, 6th year student of II medical faculty, Kharkiv, Ukraine

Objective: Therapy of pain syndromes involves exposure to its source, receptors and peripheral fibers. Treatment of acute pain and inflammation involves the use of non-steroidal anti-inflammatory drugs (NSAIDs) and non-narcotic analgesics (NNA). An alternative to obsolete analgesics is combined compositions. Analysis of experimental results clearly indicates that caffeine effectively enhances the analgesic activity of the peripheral origin when combined in a pharmaceutical composition.

The aim of the present study was to evaluate the peripheral analgesic activity of meloxicam, piroxicam and their pharmacological compositions with caffeine.

Materials and methods: The peripheral analgesic activity of piroxicam, meloxicam and their composition with caffeine was studied using the abdominal writhing test. This method used to induce pain of peripheral origin by intraperitoneal injection of 0.6 % acetic acid solution. Investigated drugs, their composition and 3 % starch mucilage were administrated 1 hour before the introduction of the algogene. The cumulative number of writhing responses induced by acetic acid were determined over next 20 min.

Results: All investigated drugs showed a decrease of writhing in rats. Meloxicam and caffeine showed peripheral analgesic activity 63.6% and 64.5% respectively (P < 0.05). The pharmaceutical composition of meloxicam and caffeine showed the analgesic potential 76.4%. Thus, the caffeine potentiates the analgesic activity of meloxicam. Obtained results exceeded the corresponding value of diclofenac sodium (67.3%).

Conclusion: Analysis of experimental results clearly indicates that caffeine effectively enhances the analgesic activity of the peripheral analgesic action of meloxicam when combined in a pharmaceutical composition. Results can serve as foundation for development of new domestic combined drugs.

Key words: meloxicam, piroxicam, caffeine, pharmaceutical composition, analgesic activity.

Giriş
Ağrı sendromlarının tedavisi, ağrı kaynağına maruz kalan reseptörler ve periferal lifleri içermekteidir. Akut ağrı ve yanmakın tedavisi, nonsteroidal antinfiammatuar ilaçların (NSAID'ler) ve narkotik olmayan analjeziklerin (NNA) kullanımı içerir. Eski analjeziklere alternatif, kombine kompozisyonlardır. DeneySEL sonuçları analiz, kafeinin, farmasötik bir bileşinde birleştirildiğinde, periferik orijinli analjezik aktivitelerini etkin bir şekilde artırırdığı açıktır kişi ve vermektedir. Bu çalışmamın amacı, meloksikam, piroksikam ve bunların kafeinle yapılıkları bileşimlerinin periferal analjezik aktivitesini değerlendirilmiştir.

Malzemeler ve yöntemler: Piroksikam, meloksikam ve bunların kafeinle yaptıkları bileşimlerin periferal analjezik aktivitesi abdominal ağrı testi kullanılarak incelenmiştir. Bu yöntemde, periferik orijini ağrıın oluşturulması % 0.6’lık asetik asit tarafından indüklenen kümülatif ağrı cevapları, sonraki 20 dakika boyunca belirlenmiştir. İncelenen ilaçlar, bunların bileşimleri ve % 3 nişasta müsilajı, algojenin verilmesinden 1 saat önce uygulandı. Asetik asit tarafından indüklenen kümülativ ağrı cevapları, sonraki 20 dakika boyunca belirlenmiştir.

Sonuçlar: İncelenen tüm ilaçlar, sınıflara göre azalması gösterdi. Meloksikamın ve kafeinin periferal analjezik aktiviteyi sırasıyla % 63.6 ve % 64.5 olarak bulunmuştur (P <0.05). Meloksikam ve kafeinin farmasötik bileșim, % 76.4’lük analjezik potansiyel göstermiştir. Bu nedenle dolaylı kafein, meloksikamın analjezik aktivite potansiyellerini artırmasıdır. Elde edilen sonuçlar diklofenak sodiyumla elde edilen değerden (% 67.3) fazladır. Sonuç: DeneySEL sonuçları analizi, kafeinin, farmasötik bileşimde meloksikamla birleştirildiğinde meloksikamın periferal analjezik etkisini etkin bir şekilde artırırdığı göstermiştir. Sonuçlar yeni yerli kombine ilaçlar geliştirmesinde temel olabilir.

INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) and non-narcotic analgesics (NNA) are widely used for the treatment of inflammation and pain syndromes. The analysis of scientific literature has shown that polycomponent compositions are more effective than monopreparations in treating pain. Therefore, the development of new effective domestic multicomponent drugs with a minimum number of side effects is a very actual question⁴. It is known that caffeine improves the analgesic effect of NNA. The mechanism of potentiation of analgesic effects is associated with an improvement of the NNA bioavailability in the combination with caffeine, and with the effect of caffeine on adenosine receptors (the so-called “purine analgesia”)⁵-⁹. Study of the biological effects
of caffeine and its pharmacological compositions showed a positive effect on the central nervous system. Caffeine shows wide range of action: reduction of adenosine transmission, regulation of excitation processes in the cerebral cortex; in corresponding doses it enhances positive condition reflexes and increases motor activity. The aim of our work was the experimental investigation of the peripheral analgesic activity of oxicams (meloxicam, piroxicam), caffeine and their pharmacological compositions.

**MATERIALS AND METHODS**

An experimental study of analgesic activity was conducted on laboratory animals – mature rats. The peripheral analgesic activity was studied by the changes in nociceptive reactions of rats. The comparative characteristic of the analgesic activity of meloxicam, caffeine and their pharmacological composition was studied using acetic acid induced abdominal writhing test. Writhes were caused by a single intraperitoneal injection of 0.6 % acetic acid solution (1 ml per 100 g of animal weight) in rats. The investigated drugs, their composition, and 3 % starch mucus were injected via gastric tube to intact animals of the first group. Experimental drugs and their composition were administrated to animals of groups 2–7 once via gastric tube: animals of the second group received piroxicam (1.3 mg per 1 kg of animal weight), 3rd - meloxicam (0.6 mg per 1 kg of animal weight), 4th - caffeine (0.6 mg per 1 kg of animal weight), 5th - the composition of piroxicam (1.3 mg per 1 kg of animal weight) with caffeine (0.6 mg per 1 kg of animal weight), 6th - the composition of meloxicam (0.6 mg per 1 kg of animal weight) with caffeine (0.6 mg per 1 kg of animal weight), 7th - a reference drug – diclofenac sodium (8 mg per 1 kg of animal weight).

An experimental activity was estimated by the ability of oxicams (meloxicam, piroxicam), caffeine, their pharmacological composition and sodium diclofenac to reduce the number of writhes in experimental animal groups as compared to the control group and expressed in percentage by the formula:

$$AA = \frac{Cc - Ce}{Cc} \cdot 100\%,$$

where AA – analgesic activity %;

Cc – the average number of writhes in the control group;

Ce – the average number of writhes in the experimental group [9-10].

In addition, the analgesic activity of oxicams, caffeine was compared with analgesic activity of their composition (meloxicam + caffeine and piroxicam + caffeine) and reference drug.

The study was carried out in accordance with the methodological recommendations of the State Pharmacological Center of the Ministry of Health of Ukraine. Economical approach, bioethical rules and statistics requirements were considered when choosing number of animals and their allocation to the treatment groups.

The study was performed on laboratory animals from experimental biological clinic of KhNPU. Rats were housed under the strict norms of the storage, care and feeding according to the principles of “European Convention for the Protection of Vertebrate Animals used for experimental and other scientific purposes” (Strasbourg, 1986) and the decision of the first National congress on Bioethics (Kyiv, 2007). Room temperature was maintained at 23-25 °C, room lighting was 100 Lx, the animal cage - 20-40 Lx. The laboratory animals were housed for 1.5 months: acclimatization period – 2 weeks; the main diet – vegetables, fodder beet; the source of water – settled tap water. Experiments were carried out in the morning, which according to the literature data corresponds to the dependence of the main pharmacological parameters and pharmacological activity of investigated drugs on circadian rhythms.

Statistical calculations were performed by conventional methods using MS Excel and Stat Graphics Plus 2.1 programs.

**RESULTS AND DISCUSSION**

A specific pain response was investigated by the method of chemical peritoneal irritation. There are several known methods of specific pain investigation: acetylcholine writhes and acetic acid-induced abdominal writhing tests. “Stretching” of animals in the acetylcholine writhes model caused by activation of the arachidonic acid metabolism with cyclooxygenase, resulting in increased synthesis of prostaglandins under the influence of acetylcholine. The mechanism of acetic acid-induced pathology activates the kinin-kallikrein system, prostaglandins, biogenic amines, leukotrienes, which are endogenous inflammatory mediators and contribute to the development of the abdominal muscle spasm, accompanied by the retraction of the hind paws and the back flexes. The effect of the investigated substances on the peripheral component of the nociceptive response was examined by the method of acetic acid abdominal writhing test, as the most informative.

In our previous studies, the central analgesic activity of caffeine in combination with piroxicam and meloxicam was studied in order to create a new medicinal composition.
The results of experimental studies have shown that administration of piroxicam, meloxicam and caffeine mono-preparations reduces number of writhes by 2, 2.6 and 2.8 times respectively compared to the control group and produce similar result as the reference drug (Fig. 1).

Figure 1 – Analgesic activity of oxicams

Such a result of caffeine peripheral analgesic activity may be associated with inhibition of the prostaglandins synthesis and TRPA1 channel, which acts as the main receptor neuropathic pain of peripheral origin. Caffeine also helps to eliminate exudate from the area of inflammation and, accordingly, reduces the compression of peripheral nociceptors. This is confirmed by our studies of the anti-exudative effect of above-mentioned compositions with caffeine\(^1\).

The analgesic activity of piroxicam (53.6%) and caffeine (64.5%) mono-preparations have similar value as reference drug – diclofenac sodium (67.3%). Composition of piroxicam with caffeine shows the reduction of writhes by 1.7 and has the lowest value of analgesic activity 40.9%. Piroxicam as a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2) has a rapid and pronounced analgesic effect. The selectivity index (inhibition ratio COX-1/COX-2) is 33, i.e, it has the highest potency against COX-1. However, literature review of nonselective NSAIDs effects indicates that the concomitant use of piroxicam with preparation having antiedemic action (caffeine) might reduce their effect. This effect could be attributed to the NSAID inhibition of renal prostaglandin synthesis and increased fluid retention. Coadministration of piroxicam with caffeine may show antagonism due to their pharmacokinetic properties. Additionally, the high affinity of caffeine to blood proteins could be a reason of antagonistic effect of this composition component on the peripheral analgesic effect\(^2\).

The addition of caffeine to piroxicam facilitates mitigation of analgesic activity, so this composition shows unpromising results in relation to analgesic activity of the peripheral genesis. The opposite data was obtained by adding caffeine to meloxicam. The meloxicam and caffeine composition has the highest value of analgesic activity 76.4% and reduces number off writhes 4.2 times.

Meloxicam is a representative of the new generation of NSAIDs - selective COX-2 inhibitors. The selectivity index (inhibition ratio of COX-1/COX-2) is 0.33; it selectively inhibits the formation of prostaglandins involved in the formation of inflammation and has a much less effect on the synthesis of prostaglandins that regulate renal blood flow, production of protective mucus in the stomach and platelet aggregation. It is known, that selective COX-2 Inhibitors doses in which selectivity is observed do not show a sufficient clinical effect. Increasing the dose leads to the loss of selectivity and the appearance of gastrotoxicity\(^3\).

Our research shows that meloxicam and its composition with caffeine in a lower dose (0.6 mg) than piroxicam (1.3 mg) and even reference drug (8 mg) exhibit higher analgesic activity. The increased analgesic effect of meloxicam composition with caffeine could be explained by effect of caffeine on the bioavailability of meloxicam and synergetic effect of these two components. Results indicate potentiation of analgesic activity of the last one, therefore this composition is considered promising for further study (Table 1).

Table 1. The investigated peripheral analgesic activity of oxicams (meloxicam and piroxicam), caffeine and their pharmaceutical compositions with caffeine
CONCLUSIONS

1. Meloxicam (dose: 0.6 mg/kg) shows peripheral analgesic activity (63.6%) at the level of reference drug (diclofenac sodium) (67.3%).
2. Meloxicam in the lowest dose (0.6 mg/kg) then piroxicam (1.3 mg/kg) demonstrates higher peripheral analgesic activity 63.6% and 53.6 correspondingly.
3. The peripheral analgesic activities of piroxicam (53.6%) and caffeine (64.5%) mono-preparations have higher values than their pharmaceutical composition (40.9%). So, further study of the analgesic activity of piroxicam with caffeine composition is considered inexpedient.
4. Pharmacological composition of meloxicam with caffeine demonstrated pain inhibition by 76.4%, that significantly exceeded the peripheral analgesic activity of the reference drug – diclofenac sodium 67.3%, i.e. caffeine effectively potentiates the analgesic activity of meloxicam. Thus, the composition of meloxicam with caffeine as a commercial source of a domestic analgesic drug could be subjected to further study.

REFERENCES

17. European convention for the protection of vertebrate animals used for experimental and other scientific purposes: Council of European. Strasbourg; 1986; 51:29-34.